: iStockAnalyst.com Symbols Feed

Closing: Late Charge Allows Stocks To End Volatile Trade On Upbeat Note

Mon, 02 Nov 2009 20:35:00 GMT

A late-day charge landed all major averages in positive territory. The DJIA advances 0.7%. The S&P 500 is up 0.6%. The Nasdaq Composite is up 0.2%.[More...]

Stocks Firmer As Bulls Enticed By Last Week's Drubbing - Ford's Beat Helps Lift Mood

Mon, 02 Nov 2009 13:31:30 GMT

Stock futures continue to point to a higher start to a week loaded with earnings and economic data. There are no early economic reports, but ISM manufacturing data and construction spending are due for release at 10 a.m. ET.[More...]

FDA Approval for Glaxo Drug

Thu, 29 Oct 2009 13:55:13 GMT

GlaxoSmithKline (GSK) and Denmark-based Genmab received some good news with the US Food and Drug Administration’s (FDA) approval?for Arzerra (ofatumumab), a monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.?[More...]

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

BioMed News Bytes: Angiotech, BioSante, HGSI

Tue, 20 Oct 2009 15:50:12 GMT

On 10/19/09, Angiotech Pharma (NASDAQ: ANPI) received notice from the FDA that Bio-Seal is a Class III medical device that requires Pre-Market Approval (PMA) for marketing clearance by the Agency.[More...]

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts

Tue, 20 Oct 2009 02:19:35 GMT

At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while expanding the pipeline and increasing the expected news flow of clinical data catalysts for the combined entity[More...]

GSK Faces New Delays (NYSE:GSK)

Fri, 02 Oct 2009 20:46:17 GMT

GSK, one of the top pharmaceutical companies, is facing new delays over the approval of their vaccine Cervarix that is aimed for the treatment of cervical cancers. GSK said that the reason for delay is because the FDA failed to complete their review on Cervarix by the anticipated deadline. However, soon GSK was dragged into deeper problems when a 14-year old school girl in UK died hours after receiving the Cervarix vaccine.[More...]

Swine Flu Helping Gilead Sciences(GILD), GlaxoSmithKline (GSK)

Mon, 28 Sep 2009 16:15:00 GMT

The Severe Acute Respiratory Syndrome (SARS) outbreak in 2003 is still fresh in our memories.[More...]

BioMed News Bytes: CUR, IPXL, QCOR, VRX

Mon, 21 Sep 2009 15:44:46 GMT

On 9/21/09, Neuralstem (AMEX: CUR) ($2.50, +34%, heavy volume) announced that the FDA has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells.[More...]

Which Pharma Pipelines Rank Best?

Thu, 17 Sep 2009 13:42:30 GMT

For the majority of pharmaceutical companies, strong pipelines should offset the approaching patent cliff.[More...]

Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years

Fri, 06 Nov 2009 11:46:00 GMT

Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC.
Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system.
The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.

[More...]

Auditor: Canada disaster planning is poor

Wed, 04 Nov 2009 15:07:00 GMT

Auditor: Canada disaster planning is poor[More...]

Vaccine-short Canada exporting 'surplus'

Wed, 04 Nov 2009 12:06:00 GMT

Vaccine-short Canada exporting 'surplus'[More...]

Largest malaria vaccine trial under way

Tue, 03 Nov 2009 15:03:00 GMT

Largest malaria vaccine trial under way[More...]

Canada's H1N1 flu vaccine running short

Fri, 30 Oct 2009 12:24:00 GMT

Canada's H1N1 flu vaccine running short[More...]

GlaxoSmithKline third quarter profit up 11 percent

Wed, 28 Oct 2009 13:51:00 GMT

LONDON - GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.
London-based Glaxo reported net profit of 1.44 billion pounds ($2.35 billion) for the three months to Sept. 30, compared to 1.29 billion pounds a year ago.
Glaxo, which has been hit by rising competition from generic versions of its previously patented drugs, is expected to receive an earnings windfall from products dashed out in response to the H1N1 flu virus.

[More...]

FDA OK's new leukemia treatment

Tue, 27 Oct 2009 11:18:00 GMT

FDA OK's new leukemia treatment[More...]

Evening Standard, London, Market Report Column

Fri, 23 Oct 2009 23:48:00 GMT

Oct. 23--Shares on the London stock market soared while the pound slumped against the dollar as the UK economy continued to reel against the worst recession on record.
That was the conclusion of financial markets on learning the shock news that the UK economy continued shrinking during the third quarter.
The move may confound the man in the street, but dealers say the Government will now have to continue with its quantitative easing programme and much of that money will find its way back into the stock market as investors look for better returns.

[More...]

Earnings Preview: Bristol-Myers 3Q earnings report

Wed, 21 Oct 2009 15:48:00 GMT

NEW YORK - Bristol-Myers Squibb Co., the world's No.
The following is a summary of key developments and analyst opinion related to the period.
OVERVIEW: Growing competition for its top drugs threatens revenue for the maker of blood thinner Plavix, the world's second-bestselling medication, and psychiatric drug Abilify.

[More...]

FDA OK's pediatric seasonal flu vaccine

Tue, 20 Oct 2009 13:13:00 GMT

FDA OK's pediatric seasonal flu vaccine[More...]

Procter &Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio

Fri, 23 Oct 2009 21:07:00 GMT

Subscribers to galtstock.com "Long-Term Portfolio" service (membership) invest in solid long-term holdings.
Other stocks in our portfolio are Procter & Gamble (NYSE: PG), Coca-Cola (NYSE: KO), GlaxoSmithKline (NYSE: GSK), and McDonald's Corp. (NYSE: MCD).
To sign up for Galt's Long-Term Portfolio service, please visit the website at http://www.galtstock.com/Long-Term-Portfolio.html with secure check out.

[More...]

Pronova BioPharma Receives 2009 Frost &Amp; Sullivan Award for Excellence in Financial &Amp; Risk Management

Tue, 08 Sep 2009 15:48:00 GMT

8 September 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or "the company") today announces that it has been awarded the 2009 Frost & Sullivan Excellence in Financial & Risk Management Award in the Global Heart Health Ingredients market for its lead product Omacor(R)/LovazaTM, the first and only EU- and FDA-approved omega-3 derived prescription drug.
The Frost & Sullivan Excellence in Financial & Risk Management Awards are presented annually to companies that demonstrate outstanding management of current market conditions, besides preparing for the future, above others within their respective industries.
This award recognises Pronova BioPharma's excellent product quality and favourable customer opinions, continued strong customer demand for Omacor/Lovaza, innovation supporting next generation omega-3 derived products (through ongoing collaborations in indications such as heart failure, atrial fibrillation and cardiac disease in type II diabetic patients) and sound operational and financial risk management practices.

[More...]

Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma

Tue, 08 Sep 2009 11:46:00 GMT

LONDON, Sept. 8 /PRNewswire/ -- The 2009 Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award is presented to Pronova BioPharma ASA.
Pronova BioPharma has demonstrated excellence in financial management.
Pronova BioPharma's return on assets (ROA) improved from 16.8 per cent in 2007 to 34.5 per cent in 2008.

[More...]

85% Profitable Trades Keep Galtstock.Com Subscribers Very Happy

Thu, 27 Aug 2009 15:09:00 GMT

The market is chopping up and down with lack of conviction, there are still great trading opportunities every week.
Subscribers to galtstock.com "SwingTrader" service (Membership) recently closed a trade in United Airlines for a 10% gain in 1 day.
Other closed trades this month were U.S. Oil Fund for 11.7% gain and FreePort-McMoran for a 10.1% profit.

[More...]

Tennis Legend John McEnroe Tells Men to 'Get Serious' About Prostate Cancer

Thu, 27 Aug 2009 13:28:00 GMT

Seven-time grand slam winner John McEnroe, whose father was diagnosed with prostate cancer in 2006, is providing his voice and image to a new campaign that promotes recently updated prostate-cancer screening guidelines.[More...]

GSK Advisory: Warehouse Theft

Mon, 24 Aug 2009 20:26:00 GMT

GlaxoSmithKline is advising that two lots of Advair Diskus medication were stolen on August 2 from the company's distribution facility near Richmond, Virginia. Medicine in the stolen cartons could represent a health risk because it has been removed from the legitimate supply chain and the storage conditions under which the stolen products were held are unknown. Inhalers from these lots should not be dispensed, sold, or used.[More...]

Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy

Thu, 20 Aug 2009 20:33:00 GMT

EXTON, PA and PHILADELPHIA, PA -- -- 08/20/09 -- Adolor Corporation and GlaxoSmithKline today announced that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel resection surgery decreased the amount of time patients spent in the hospital by one day, resulting in lower estimated hospital costs compared with placebo. The results, published in the American Journal of Health-System Pharmacy, were based on a post-hoc pharmacoeconomic analysis of pooled data consisting of 1,409 patients who participated in four randomized, double-blind, placebo-controlled, Phase 3 efficacy studies of ENTEREG conducted in North America.[More...]

Video: FDA Approves GSK's Hib Vaccine, Hiberix(R)

Thu, 20 Aug 2009 00:09:00 GMT

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b , GlaxoSmithKline has received accelerated approval from the FDA for Hiberix) [Haemophilus b Conjugate Vaccine ] as a booster dose in children 15 months through four years of age.Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.[More...]

Pharmerging Versus Mature Pharmaceutical Markets: Where Is Pharma Going? Where Is Pharma Growing? -- an Industrial Info News Alert

Wed, 12 Aug 2009 11:52:00 GMT

Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- One of the latest trendy phrases zipping around the Pharmaceutical Industry is "pharmerging markets."
The pharmerging areas are poised to receive the next major influx of capital activity from all of the Pharmaceutical Industry majors, e.g. Pfizer Incorporated (NYSE:PFE), GlaxoSmithKline plc (NYSE:GSK), Merck & Company Incorporated (NYSE:MRK), albeit with a definite risk of losing both intellectual and physical property.
For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showNews.jsp?newsitemID=149279, or browse other breaking industrial news stories at www.industrialinfo.com.

[More...]

StockPreacher.com Issues Trading Outlook for ViroPharma Inc.

Tue, 04 Aug 2009 10:46:00 GMT

StockPreacher.com announces an investment report featuring biopharmaceutical company ViroPharma Inc. . The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.[More...]